Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2013, Pages 294-299

  Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; EPRATUZUMAB; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; RITUXIMAB;

CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTOXINS; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RITUXIMAB; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84891875791     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.1200/EdBook_AM.2013.33.294     Document Type: Review

References (0)